Cancer is a disease that results from both genetic and epigenetic changes. Discordant phenotypes and varying incidences of complex diseases such as cancer in monozygotic twins as well as genetically identical laboratory animals have long been attributed to differences in environmental exposures. Accumulating evidence indicates, however, that disparities in gene expression resulting from variable modifications in DNA methylation and chromatin structure in response to the environment also play a role in differential susceptibility to disease. Despite a growing consensus on the importance of epigenetics in the etiology of chronic human diseases, the genes most prone to epigenetic dysregulation are incompletely defined. Moreover, neither the environmental agents most strongly affecting the epigenome nor the critical windows of vulnerability to environmentally induced epigenetic alterations are adequately characterized. These major deficits in knowledge markedly impair our ability to understand fully the etiology of cancer and the importance of the epigenome in diagnosing and preventing this devastating disease.
I t was initially thought that complete sequencing of the human genome would result in the ready identification of the molecular events involved in human disease formation; however, it is now clear that the etiology of most human pathologic conditions will not be fully understood by simply analyzing genomic DNA sequence for genetic variants. This is because mammalian genomes are also subject to DNA methylation and histone modifications that significantly alter gene function. Thus, cell phenotype is not only dependent on its genotype but also on its unique epigenotype, which is shaped by developmental history and environmental exposures.
The role of epigenetic gene regulation in the etiology of cancer is increasingly being recognized. The most commonly described epigenetic change in cancer is an alteration in the methylation pattern of DNA cytosine residues. The covalent addition of a methyl group to the C5 position of cytosine ( Fig.  1A ) occurs most frequently in CpG islands (cytosine-phosphate-guanine islands), and it results in a conformational change in the major groove of DNA that alters protein binding. CpG islands are regions in the genome with a high GC content and frequent CpG occurrence. 1 The human and mouse genome projects identified approximately 15,500 and 29,000 CpG islands, respectively. [2] [3] [4] Hypermethylation of CpG-rich regions of gene promoters inhibits expression by blocking the initiation of transcription. DNA methylation is also involved in the allelic inactivation of imprinted genes, the silencing of genes on the inactive X chromosome, and the reduction of expression of transposable elements. 5, 6 DNA methyltransferase (DNMT) enzymes catalyze the covalent addition of a methyl group to the C5 position of a cytosine residue (Fig. 1A) . The activities of the 2 major types of DNMT enzymes result in either DNA methylation maintenance or de novo addition of methyl groups to genomic DNA. 7 After de novo methylation, which is catalyzed by DNMT3L, DNMT3A, and DNMT3B, the DNMT1 maintenance enzyme preserves methylation at CpG sites by recognizing postreplicative, hemimethylated sequences ( Fig. 1B ). Because these epigenetic modifications are copied after DNA synthesis by DNMT1, they are inherited during somatic cell replication.
Epigenetic modification of cellular phenotype is also driven by alterations in chromatin structure via covalent modification of histone proteins and reorganization of nucleosomes ( Fig. 2 ). Histone acetylation is usually associated with transcriptional activation because the affinity of acetylated histone proteins for DNA is reduced and chromatin packaging is thus relaxed. Histone methylation results in various transcriptional consequences depending on which histone is affected and which lysine residue is modified. For example, histone H3 methylation at lysine 9 is associated with hetero-chromatin, a more compact formation of chromatin, and subsequent gene silencing. Furthermore, methylated DNA recruits methyl cytosine binding protein 2, which binds histone deacetylases (HDACs) and associated corepressor proteins, resulting in transcriptional repression. In contrast, histone H3 methylation at lysine 4 or lysine 27 is associated with transcriptional activation. Histone lysine residues may be methylated in the form of monomethylation, dimethylation, or trimethylation, adding enormous complexity to the histone code. 8 Moreover, multisubunit chromatin-protein complexes, such as the repressive polycomb group proteins or the activating SWI-SNF proteins, add yet another layer of complexity to epigenetic gene regulation (see reviews 8 -10 ). These epigenetic modifications therefore provide an intricate and reversible mechanism for modulating gene expression in response to intracellular or extracellular cues.
EPIGENETICS AND NEOPLASIA
Inherited and spontaneous or environmentally induced epigenetic alterations are increasingly being recognized as early molecular events in cancer formation. 11, 12 Furthermore, such epigenetic alterations are potentially more adverse than nucleotide mutations because their effects on regional chromatin structure can spread, thereby affecting multiple genetic loci. 13 Transcription of a number of tumor suppressor genes such as p16 INK4a , BRCA1, p53, and hMLH-1 has now be demonstrated to be inhibited by promoter hypermethylation. 5 Although tumor suppressor gene silencing by DNA methylation occurs frequently in cancer, genome-wide hypomethylation is one of the earliest events to occur in the genesis of cancer. 14 -16 Demethylation of the genome can lead to the reactivation of transposable elements, thereby altering the transcription of adjacent genes, the activation of oncogenes such as H-RAS, and biallelic expression of imprinted loci (eg, loss of IGF2 imprinting). 14, 15, 17 Furthermore, genomic instability associated with the hypermethylation of the DNA mismatch repair enzyme gene MLH1 may deregulate not only critical genes involved in the initial stages of carcinogenesis but also those involved in the later invasion and metastasis stages of transformation. 18 Posttranslational histone modifications such as histone deacetylation and inappropriate remodeling of chromatin structure also lead to a wide range of neoplasias, including rhabdoid tumors (influenced by mutations in the activating SWI-SNF chromatin protein complex), chronic myeloid leukemia, retinoblastoma, and lung, breast, and prostate cancer. 19 -21 The human breast cancer susceptibility protein BRCA1 is a stable component of the SWI-SNF chromatin complex. 22 In cells transfected with a dominant-negative version of the SWI-SNF ATPase, BRCA1 is not able to synergize with the tumor suppressor p53, a process that has previously been demonstrated to activate transcription. 23 Additionally, mutated SWI-SNF complexes disrupt c-Myc transactivation. 24 Together, these data strongly indicate that dysregulation of chromatin remodeling activity promotes cancer. Furthermore, treatment with HDAC inhibitors, such as trichostatin-A, stimulates reactivation of the actin-binding protein gelsolin (a candidate suppressor of breast cancer). 25, 26 
EPIGENETICALLY LABILE CANCER SUSCEPTIBILITY LOCI
Two distinct sets of genes that potentially link environmental exposures during pregnancy to adult disease susceptibility are imprinted genes and genes with metastable epialleles. Genes with metastable epialleles have highly variable expression because of stochastic allelic changes in the epigenome. 27 In contrast, imprinted genes have monoallelic, parent-of-origin-dependent expression, and they are functionally haploid. 28, 29 This is particularly important because imprinting eliminates the protection normally afforded by diploidy against the deleterious effects of recessive mutations ( Fig. 3 ).
Imprinted Genes
Imprinting can be deregulated in both germ cells and somatic cells. Because imprinted genes are frequently clustered and their expression is coordinately regulated by imprinting control regions, a single genetic or epigenetic change in an imprinting control region can result in the disruption of many genes. Consequently, imprinted genes are associated not only with severe complex developmental disorders such as Angelman, Beckwith-Wiedemann, and Prader-Willi syndromes but also with cancer. 28, 29 Imprinted genes are at a much greater risk of somatic cell inactivation by mutation, loss of heterozygosity, and epigenetic alterations because one allele is already inactivated by genomic imprinting (Fig. 3 ). The silent, imprinted allele is frequently equated to the first hit in Knudson's 2-hit hypothesis for oncogenesis ( Fig. 3) . 30 Because imprinted genes normally encode for either positive or negative growth effectors, they are frequently involved in the formation of a wide range of tumors. 28 Aberrant methylation upstream of the maternally expressed H19 gene is associated with the development of pediatric Wilms tumors in patients with Beckwith-Wiedemann syndrome because it results in loss of imprinting at the IGF2 locus. 31 IGF2 biallelic expression is also involved in a number of adult-onset cancers, including colorectal carcinoma, bladder cancer, osteosarcoma, and breast cancer. 15, 29, 32, 33 DLK1 is overexpressed in neuroendocrine tumors, suggesting a potential oncogenic role. 34 In contrast, ARHI 35 and ZAC1 36 are imprinted genes that function as tumor suppressors in human breast and ovarian cancer. NNAT may also provide a tumor suppressor function because it is frequently subject to promoter hypermethylation with concomitant decreased expression in myeloid and lymphoid acute leukemia. 37 There is also genetic evidence that IGF2R, which is imprinted in mice but not in humans, 38 functions as a tumor suppressor gene, as demonstrated by frequent loss of heterozygosity and mutations in a number of human 39 -45 and rodent 46, 47 cancers. The loss of IGF2R imprinting in the primate lineage (ie, humans have 2 functional alleles) indicates that humans would be more resistant to cancers involving this tumor suppressor than mice that are still imprinted at this locus. 38, 48 Thus, the divergent evolution of IGF2R brings into question the relevance of human carcinogen risk assessments based solely on nonprimate animal studies. 28, 38 
Metastable Epialleles
Metastable epialleles are genetically identical alleles that are variably expressed because of different epigenetic modifications established during early development. 27 These metastable epialleles can also be environmentally modified later in life. 49 The establishment of an epigenotype at each allele is stochastic and can be associated with widely varying phenotypes ( Fig. 4 ). Furthermore, the epigenetic modifica- 50, 51 This incomplete erasure can lead to transgenerational epigenetic inheritance. Metastable epialleles are most often associated with retroelements and transgenesis. Three of the identified murine metastable epialleles (A vy , Axin Fu , and Cabp IAP ) are associated with contraoriented intracisternal A particle (IAP) retrotransposon insertions. IAP proviral elements are prevalent in the mouse genome and consist of the full-length 7-kilobase elements as well as shorter elements with deletions of varying lengths. 52 Approximately 1000 copies of IAP retrotransposons are present in the mouse genome, 52 and about 9% of the human genome contains retrotransposons. 53 IAP transcripts have been identified in most murine tissues, 52 and they are increased dramatically in DNMT knockout mice. 54 The long terminal repeats of IAPs carry promoters that initiate transcription of the IAP and in some cases adjacent host sequences, 55 contain multiple protein binding sites, 56 and are influenced by methylation status. 57 In fact, IAP hypomethylation at the 5Ј long terminal repeat has been attributed to constitutive expression of IAP transcripts in many mouse tumors. 52, 57 The murine Agouti gene encodes a paracrine signaling molecule that promotes follicular melanocytes to produce yellow pheomelanin pigment instead of black eumelanin pigment. Transcription is normally initiated from a hair-cycle-specific promoter in exon 2 of the Agouti (A) allele (Fig. 4A ). Transcription of the Agouti gene normally occurs only transiently in hair follicles during a specific stage of hair growth. It results in a subapical yellow band on each black hair shaft, causing the brown (agouti) coat color of wild-type mice. 58 The A vy allele resulted from the insertion of an IAP murine retrotransposon upstream of the transcription start site of the Agouti gene ( Fig. 4A ). 58, 59 A cryptic promoter in the proximal end of the A vy IAP promotes constitutive ectopic Agouti transcription, leading to yellow fur. 51, 60 Moreover, CpG methylation in the A vy IAP correlates inversely with ectopic Agouti expression. The degree of methylation varies dramatically among individual isogenic A vy /a mice, causing a wide variation in coat color ranging from yellow (unmethylated IAP) to pseudoagouti (methylated IAP) ( Fig. 4B ). 51 Yellow animals with hypomethylation at the cryptic promoter also experience increased incidence of obesity, diabetes, and tumorigenesis, whereas genetically identical brown pseudoagouti animals with hypermethylation in the same region are protected from these pathologic conditions. 51, 60, 61 The identification and categorization of additional metastable epialleles in the mouse, as well as the human genome, will significantly enhance our understanding of how epigenetic lability contributes to human health and disease, including cancer.
CANCER SUSCEPTIBILITY AND THE ENVIRONMENT
The epigenome is particularly susceptible to dysregulation by environmental factors during gestation, neonatal development, puberty, and old age. In fact, age-correlated increases in DNA promoter methylation occur in a number of genes involved in cancer, including IGF2, Versican, and PAX6, among others. 13 Alterations in epigenotype have also been observed after adult exposure to environmental xenobiotic chemicals. Exposure of adult mice to sodium arsenite in vivo revealed decreased genomic methylation, whereas coexposure to sodium arsenite and a methyl-deficient diet showed gene-specific hypomethylation in the promoter region of the oncogenic gene, Ha-ras. 62 Other metals, including cadmium, 63 lead, 64 and nickel, 65 have also been shown to interact with the epigenome. In addition, decreased histone acetylation, increased histone methylation, and subsequent decreased gene expression occur after in vitro nickel exposure. 66, 67 Furthermore, in vitro chromium exposure is linked to epigenetically controlled gene expression alterations via interactions with histone acetyltransferase and HDAC enzymes. 68 Although alterations in the epigenome can occur during adulthood, it is most vulnerable to environmental factors during embryogenesis because the DNA synthetic rate is high and the elaborate DNA methylation patterning required for normal tissue development is established during early development. Endocrine active chemicals have been associated with epigenetic alterations after in utero exposures. Methylation studies conducted with the estrogenic pharmaceutical agent diethylstilbestrol (DES) demonstrated hypomethylation in the estrogen-responsive lactoferrin promoter and in the promoter and intronic regions of the c-fos oncogene in mice exposed in utero or in the perinatal period, respectively 69, 70 ; however, significant methylation changes after neonatal DES exposure were not observed in the murine abdominal B-like Hoxa genes, important regulators of reproductive tract development. 71 Human epidemiologic evidence reveals that individuals exposed to DES in utero during the first 3 months of pregnancy exhibited increased incidences of reproductive disorders and the rare cancer, clear cell adenocarcinoma of the vagina. 72 Increased incidences of uncommon disorders were also seen in the granddaughters and grandsons of DESexposed women, suggesting epigenetic transgenerational inheritance. 72 Rodent studies likewise demonstrated that the effects of maternal DES exposure are transmitted through the maternal germline to offspring via both genetic and epigenetic mechanisms. 73 Recently, the chaperone protein, Hsp90, was associated with DES-induced epigenetic gene alterations via interactions with histone proteins important for active chromatin conformations. 74 The effects of dietary exposure to naturally occurring plant-based phytoestrogens, including the isoflavinoid genistein, are also of growing interest. We recently demonstrated that maternal genistein supplementation of mice during gestation, at levels comparable to those of humans consuming high soy diets, shifted the coat color of viable yellow Agouti (A vy /a) offspring toward pseudoagouti by increasing methylation of 6 CpG sites in a retrotransposon upstream of the metastable Agouti gene (Fig. 4A ). 75 The genistein-induced hypermethylation additionally protected A vy /a animals from obesity and tumorigenesis in adulthood.
Exposure to endocrine active compounds has recently been linked with epigenetic alterations that are inherited transgenerationally even in the absence of continued exposure. Anway et al 76 reported that maternal transient exposure to the antiandrogenic fungicide vinclozolin or the estrogenic pesticide methoxychlor during reprogramming of the germline resulted in increased spermatogonial germ cell apoptosis and decreased epididymal sperm count and motility in not only the first generation but also in generations 2 through 4. The high frequency of these phenotypic changes in subsequent generations and altered methylation patterns in the sperm that persisted transgenerationally excluded genetic mutations as the cause of these pathologic conditions.
EPIGENETIC BASIS FOR CANCER TREATMENT, DIAGNOSIS, AND PREVENTION
Our enhanced understanding of the importance of epigenetics in the etiology of cancer has ushered in a new era in which treatment, diagnosis, and prevention are focused not solely on the genome but also on the epigenome. Typical cancer treatment involves either broad therapies such as surgery, radiation, and chemotherapy or more specific individualized therapy targeting specific genetic mutations and more recently epimutations. Broad epigenetic therapeutic approaches, some of which are currently approved for human use, include DNA methylation inhibition 77 and HDAC inhibition. Epigenetic therapies are also undergoing development to target directly specific sites in the genome, including the directed silencing of oncogenes via DNA methylation.
DNA methylation inhibition therapies involve both nucleoside and nonnucleoside analogs. The archetypal DNMT inhibitor 5-azacytidine is a nucleoside inhibitor that is incorporated into DNA. Upon incorporation, both cytosine and 5-azacytidine residues are methylated by DNMTs; cellular DNMT is rapidly depleted because of its inactivation by bonding in covalent protein-DNA adducts. 78 The side effects of accumulated nucleoside inhibitor enzymes, however, are often toxic, as manifested by myelosuppression with neutropenic fever. 79 Nonnucleoside DNMT inhibitors (hydralazine, 80 procainamide, 81 and epigallocatechin-3-gallate 82 ) interfere with DNMT activity by binding directly to the enzymes instead of incorporating into the DNA sequence itself. Because these compounds directly block DNMT activity as opposed to covalently binding DNA, nonnucleoside DNMT inhibitors appear to be less toxic.
HDAC inhibitors are a structurally diverse group of compounds, including cyclic and noncyclic hydroamates, shortchain fatty acids, cyclic peptides, and benzamides. 83 A number of HDAC inhibitors have now been demonstrated to inhibit histone deacetylation in human tumor cells, 84 -86 although the development of HDAC inhibitors is still in early preclinical stages. Treatment with nucleoside or nonnucleoside methylation inhibitors followed by HDAC inhibitors often yields additive or synergistic effects in reexpression of silenced tumor suppressor genes. 78, 87 In addition, cotreatment with HDAC inhibitors and other chemotherapeutic agents results in additive and sometimes synergistic therapeutic responses. 83 Finally, HDAC inhibitor treatment may protect normal cells from the toxic side effects of ionizing radiation. 83 Specific epimutations have been documented for a variety of cancers, and, as a consequence, novel therapeutic measures are being developed to target directly specific sites in the genome. Inhibition of inappropriate transcriptional initiation of growth factors (IGF2) 88 and various oncogenes, such as BCL-2, 89 , by directed DNA methylation is a precise and heritable therapeutic alteration of the epigenome. Although not yet approved for therapeutic human use, directed epigenetic gene therapy holds tremendous promise for enhancing cancer prevention and therapy.
Epigenetic alterations not only are ideal targets for cancer therapeutics but can also serve as biomarkers for cancer diagnosis and targets for prevention. The phenomenon of interindividual variability in methylation and expression may represent a common characteristic of epigenetically labile genes in the mouse and human genomes whose expression is controlled by DNA methylation or other epigenetic 49 It has been demonstrated that epigenetic discordance, including differences in DNA methylation and histone modification patterns, is present between monozygotic twins and that this discordance increases with age and is associated with differences in disease incidence 90, 91 ; therefore, identifying the epigenetic molecular changes associated with aging and cancer will have important implications for future diagnostic and prevention strategies. Additionally, gestation represents a "developmental window of vulnerability" to epigenetic changes that are modifiable by nutritional and environmental factors. 59, 75, 92, 93 In principle, epigenetic changes established during gestation and neonatal development are also reversible in adulthood, as demonstrated by studies showing that epigenetic marks influenced by neonatal maternal behavior are reversed in adulthood after methionine or HDAC inhibitor infusion 94 -96 ; therefore, understanding specific epigenetic mechanisms that affect clinical outcomes may ultimately enable early-life nutritional interventions to prevent adult-onset cancers in humans. 49
PROFILING THE HUMAN EPIGENOME
As discussed here, epigenome dysregulation is implicated in a broad range of cancers. 14 -16,97-99 Currently, primary cancer therapies focus on the genetic basis of how individuals respond to drug treatment. Small epigenetic variations, however, have the capability to influence, for example, the way an individual metabolizes drugs, and identifying such variations has potential applications in drug development research and in medical treatment. An individual's epigenetic profile might help predict whether a particular drug is likely to be effective or likely to cause an adverse reaction. The identification of environmentally responsive, epigenetically labile genes in both the mouse and human genomes should ultimately allow for improved diagnosis, treatment, and prevention of chronic human diseases such as cancer. One robust method for accomplishing this objective makes use of machine-learning algorithms trained to identify genomic motifs that are predictive of imprinted genes and metastable epialleles.
We recently developed such a bioinformatic approach for interrogating the entire mouse genome to identify genes with high probabilities of being imprinted. 100 A number of genes identified in this study have human homologs that show linkage to diseases. Furthermore, many of these orthologs share CpG islands or transposable elements in syntenic regions within 10 kilobases of their promoters, arguably 2 of the most straightforward target elements for epigenetic control of adjacent gene expression. Because genomic imprinting is epigenetically regulated, 28,101 these putative imprinted genes may be especially vulnerable to environmental influences. The detection of a comparable genome-wide set of epigenetically labile metastable epialleles in mice and humans will allow us to establish their role in human health and to also determine better the value of the mouse as a model for assessing human risk from agents that elicit their biologic effect primarily by altering the epigenome. Although we do predict some overlap between mouse and human candidate imprinted genes identified through our machine-learning approach, it is likely that the most significant criterion in species-specific identification will differ. This difference underscores the importance for increased caution when assessing human risk from environmental agents that alter the epigenome using rodent models; the molecular pathways targeted may be independent.
To this end, the Human Epigenome Project (http:// www.epigenome.org/index.php) seeks to identify, catalog, and interpret genome-wide DNA methylation patterns of all human genes in all major tissues. Although providing a solid platform for analysis, this approach would be incomplete without further identification of environmentally responsive epigenetically labile loci in the human genome.
